By: IPP Bureau
Last updated : August 10, 2026 8:09 pm
Profit before exceptional items and tax stood at Rs. 510 million, while profit after exceptional items and tax was Rs. 507 million during the quarter.
AstraZeneca Pharma India Limited has reported a 30% year-on-year growth in total revenue from operations to Rs. 6,828 million for the quarter ended June 30, 2026, marking a strong start to FY2026-27.
The science-led biopharmaceutical company said the performance was driven by continued momentum across its core therapy areas, including Oncology, Biopharmaceuticals covering cardiovascular, renal and respiratory diseases (CVRM and R&I), and Rare Disease. The company attributed the growth to its innovation-led strategy, disciplined execution and focus on improving patient outcomes in India.
Profit before exceptional items and tax stood at Rs. 510 million, while profit after exceptional items and tax was Rs. 507 million during the quarter.
On a therapy-area basis, Oncology remained the largest contributor, generating revenue of Rs. 4,649 million, up 26% year-on-year.
Biopharmaceuticals revenue increased 36% to Rs. 1,619 million, while Rare Disease revenue stood at Rs. 144 million, representing a 35-fold increase compared with the corresponding quarter last year.
Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma India, said, “We delivered 30% growth in the first quarter, bringing our revenue to INR 6,828 Mn. This performance builds on our strong track record of delivering a consistent double-digit growth over the last four years. Our focus remains on investing strategically in opportunities that support sustainable long-term value creation.”
Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India, said, “Our purpose is to push the boundaries of science to deliver life-changing medicines, and this shapes how we serve unmet patient needs in India. The growth and momentum in the first quarter reflects the strength of our portfolio and focus on expanding access to serve more patients in India.”
During the quarter, AstraZeneca Pharma India strengthened its portfolio with several regulatory approvals. Acalabrutinib received approval in combination with venetoclax, with or without obinutuzumab, for previously untreated chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
The company also received approval for acalabrutinib in combination with bendamustine and rituximab for previously untreated mantle cell lymphoma (MCL) patients who are not eligible for autologous stem cell transplant.